Update on alternative therapies for vulvovaginal atrophy

Figures & data

Table 1 Alternative therapies for vulvovaginal atrophy in clinical development

Drug name	Drug category	Route of administration	Pharmaceutical company	Clinical phase
Ospemifene	SERM	Oral	QuatRx™ Pharmaceuticals Co, Ann Arbor, MI	NDA
BZA/CE	STEAR	Oral	Pfizer, Inc, New York, NY	Phase III
Prasterone^®	Androgen derivative	Vaginal	EndoCeutics, Inc, Quebec, Canada	Phase III
Seale^®	SERM	Vaginal	Bionovo, Inc, Emeryville, CA	Phase I–II

Abbreviations: BZA/CE, bazedoxifene/conjugated estrogens; NDA, new drug application; SERM, selective estrogen receptor modulator; STEAR, selective tissue estrogenic activity regulator.